Q1 Earnings Forecast for SABS Issued By HC Wainwright

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of SAB Biotherapeutics in a research note issued on Wednesday, January 29th. HC Wainwright analyst E. White expects that the company will earn ($1.35) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2025 earnings at ($1.32) EPS, Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($1.34) EPS, FY2025 earnings at ($5.31) EPS and FY2026 earnings at ($4.03) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%.

SABS has been the subject of several other reports. Chardan Capital reissued a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a research note on Wednesday. Craig Hallum began coverage on shares of SAB Biotherapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Stock Down 2.7 %

NASDAQ:SABS opened at $2.17 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. The stock’s fifty day moving average is $3.61 and its two-hundred day moving average is $3.12. SAB Biotherapeutics has a 52 week low of $2.00 and a 52 week high of $6.30.

Institutional Investors Weigh In On SAB Biotherapeutics

An institutional investor recently raised its position in SAB Biotherapeutics stock. HB Wealth Management LLC raised its holdings in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 118.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 237,400 shares of the company’s stock after acquiring an additional 128,800 shares during the quarter. HB Wealth Management LLC owned approximately 2.57% of SAB Biotherapeutics worth $982,000 as of its most recent filing with the Securities and Exchange Commission. 7.82% of the stock is owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.